Status:
TERMINATED
Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Lead Sponsor:
UConn Health
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Ovarian Cancer
Peritoneal Cancer
Eligibility:
FEMALE
19+ years
Phase:
PHASE2
Brief Summary
The primary objective is to determine whether the addition of bevacizumab to a regimen of carboplatin plus paclitaxel significantly improves Progression Free Survival (PFS) for patient with Stage III ...
Detailed Description
The aim of this study is to determine if the addition of bevacizumab to a regimen of carboplatin/paclitaxel increases the time to disease recurrence (longer remission for patients) in women that have ...
Eligibility Criteria
Inclusion
- diagnosis of primary peritoneal carcinoma, fallopian tube epithelial ovarian carcinoma,
- stage III suboptimal surgery or biopsy,
- stage IV disease
- no prior chemotherapy
Exclusion
- unstable heart conditions
- high blood pressure
- vascular disorders
- bleeding problems
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00408070
Start Date
October 1 2006
End Date
October 1 2009
Last Update
March 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030